Citations

Showing 10 of 108152 citations.

Patch-Testing with Plastics and Glues Series Allergens
Shmidt, Eugenia , Farmer, Sara A., Davis, Mark D.P.

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 21 | Issue: 5 | Pages: 269-274

10.2310/6620.2010.10024 Get It

Background: Few US studies have reported results of patch testing with plastics and glues. Objective: To report our institution's results of testing patients suspected of allergy to plastics and glues with a comprehensive plastics and glues series and to compare these results with previously published data. Methods: Retrospective review of results of patch-testing with plastics and glues allergens at our institution between 2000 and 2007. In total, 444 patients were patch-tested with up to 56 plastics and glues allergens in the specialized series and up to five plastics and glues allergens in a baseline series. Positive-reaction rates were compared to other patch testing reports. Results: Of patients, 97 (22%) had irritant reactions, and 201 (45%) had at least one allergic reaction. Bis(2-dimethylaminoethyl) ether 1%, benzoyl peroxide 1%, epoxy resin, bisphenol F 0.25%, 2-hydroxyethyl methacrylate 2%, and 2-hydroxyethyl acrylate 0.1% had the highest allergy reaction rates. Testing with specialized series identified 193 patients with plastics and glues allergy, of whom 162 were not identified by testing with baseline series alone. Conclusion: For patients suspected of allergy to plastics and glues, patch-testing with specialized series of plastics and glues allergens is an important adjunct to patch-testing with baseline series.
Photopatch Testing of 182 Patients: A 6-Year Experience at the Mayo Clinic
Scalf, Leigh Ann, Davis, Mark D.P. , Rohlinger, Audrey L., Connolly, Suzanne M.

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 20 | Issue: 1 | Pages: 44-52

10.2310/6620.2008.08049 Get It

Background: Photopatch testing is important for diagnosing photoallergic contact dermatitis. Although results of photopatch testing have been presented from many European centers, there have been few reports of the results of photopatch testing in the United States. Objective: To review the Mayo Clinic’s recent experience with photopatch testing, identify common photoallergens, and compare our current and previous findings. Methods: We retrospectively reviewed records of patients who underwent photopatch testing at the Mayo Clinic between January 1, 2000, and December 31, 2005 (N=182). Results: Fifty-four patients (29.7%) had photoallergic contact reactions, and 29 (15.9%) had allergic contact reactions. The most common photoallergens were medications, sunscreen agents, fragrances, and antiseptics. Conclusion: Photopatch testing is the technique useful in identifying photoallergens. The series of allergens used must be constantly updated to reflect newly identified and outdated photoallergens. We present a 6-year experience with photopatch testing. Medications, sunscreen agents, fragrances, and antiseptics were the most frequently identified photoallergens.
Creation, History, and Future of the Contact Allergen Replacement Database (CARD)
Yiannias, James A. , Miller, Ryan , Kist, Joseph M.

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 20 | Issue: 6 | Pages: 322-326

10.2310/6620.2009.00010 Get It

An 8-Year Retrospective Review of Patch Testing with Rubber Allergens: The Mayo Clinic Experience
Bendewald, Margo J., Farmer, Sara A., Davis, Mark D. P. , Davis, Mark D.P.

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 21 | Issue: 1 | Pages: 33-40

10.2310/6620.2009.09029 Get It

Background: Allergic contact dermatitis from rubber chemicals is increasingly recognized. Objective: To review the results of patch testing with rubber allergens from January 1, 2000, through December 31, 2007. Methods: Patients who underwent patch testing with a specialized series of rubber allergens were identified. Results: In total, 773 patients (64.2% female; mean age, 48.6 years) were patch-tested with a rubber series (27 allergens), and 739 (95.6%) were concomitantly patch-tested with a standard allergen series. Commonly affected sites of dermatitis were the hand (49.7%), foot (15.9%), leg (12.0%), and arm (10.9%). The most common occupations were health care worker (16.3%) and homemaker (6.5%); 11.3% were retired. The rate of allergic reaction to at least one rubber allergen was 245 of 773 (31.7%). The allergens that most commonly yielded positive reactions were 4,4-dithiodimorpholine 1% (28/286 [9.8%]), thiuram mix (56/739 [7.6%]), and diphenylguanidine 1% (57/759 [7.5%]). Conclusion: Rubber is a frequent cause of allergic contact dermatitis. Patch testing with a rubber series improved the ability to diagnose allergic contact dermatitis caused by rubber.
Patch Testing with Natural Rubber Latex: The Mayo Clinic Experience
Bendewald, Margo J., Farmer, Sara A., Davis, Mark D. P. , Davis, Mark D.P.

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 21 | Issue: 6 | Pages: 311-316

10.2310/6620.2010.09066 Get It

Background: Delayed hypersensitivity reactions to natural rubber latex (NRL) have been recognized. These reactions may contribute to allergic contact dermatitis. We therefore have undertaken patch testing of patients with NRL if they are suspected to have allergic contact dermatitis to rubber. Objective: To review results of patch testing with NRL (January 1, 2000, through December 31, 2007). Methods: Patients suspected of having allergic contact dermatitis from rubber who underwent patch testing with NRL were identified retrospectively. For safety reasons, patients with immediate hypersensitivity to NRL were excluded from patch testing. Results: Of 148 patients patch-tested with NRL, 3 (2.0%) had an allergic patch-test reaction. Conclusions: NRL is as common a cause of allergic contact dermatitis as many of the other allergens included in a specialized rubber allergen series. Patients suspected to be allergic to rubber should be patch-tested with NRL (provided they do not have type 1 hypersensitivity to NRL).
A 10-Year Retrospective Study on Palladium Sensitivity
Durosaro, Olayemi, el‐Azhary, Rokea A. , El-Azhary, Rokea

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 20 | Issue: 4 | Pages: 208-213

10.2310/6620.2009.08108 Get It

Background: Palladium has become an important contact allergen because of increased use in industry, jewelry, and dentistry. Objective: To determine the frequency of palladium allergy in a US patch-test population tested to palladium. Methods: A 10-year retrospective review (1997–2006) was performed on patients sensitive to palladium at the Department of Dermatology, Mayo Clinic, Rochester, MN. Results: A total of 910 patients were tested to a series that included palladium chloride 2% in petrolatum. A palladium-positive patch-test result was noted in 110 patients (12.1%). Of the 106 patients sensitized to palladium who had records available for review, 15.1% had a diagnosis of lichen planus-like eruptions; 13.2%, burning mouth; 27.4%, stomatitis; and 29.2%, hand and body dermatitis. Conclusion: Palladium sensitivity is more common in oral diseases than in skin. We describe a previously unknown high degree of co-reactivity of gold with palladium to the same degree as the known co-reactivity with nickel.
Allergic Contact Dermatitis from Vitamin E: The Experience at Mayo Clinic Arizona, 1987 to 2007
Adams, Alison K. , Connolly, Suzanne M.

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 21 | Issue: 4 | Pages: 199-202

10.2310/6620.2010.10018 Get It

Background: Vitamin E, of which the most biologically active form is a-tocopherol, has become widely known for its antioxidant effects. It has been ingested or applied topically for purported anti-aging effects and for cosmetic enhancement. Objective: To determine whether the incidence of allergic contact dermatitis from vitamin E has increased in recent years. Methods: With the approval of the Mayo Clinic institutional review board, we retrospectively analyzed patch-test data from patients tested from June 1987 through December 2007. Results: A total of 2,950 patients were patch-tested during this period, and 18 patients (0.61%) had positive reactions to a-tocopherol; 6 (0.53%) of 1,136 patients tested from June 1987 through December 1997 had positive results, and 12 (0.66%) of 1,814 patients tested from January 1998 through December 2007 had positive results (p = .69). Conclusion: Vitamin E appears to be a relatively rare contact allergen in our experience.
Ten Years of Kidney Paired Donation at Mayo Clinic: The Benefits of Incorporating ABO/HLA Compatible Pairs
Prieto, Mikel , Kosberg, Catherine L., Mai, Martin L., Khamash, Hasan , Issa, Naim , Dean, Patrick G. , Lorenz, Elizabeth C. , Stegall, Mark D. , Kosberg, Catherine, Khamash, Hasan A, Issa, Naim S, Stegall, Mark D , Basu, Arpita , Mai, Martin L., Jadlowiec, Caroline C. , Schinstock, Carrie A.

Mayo Clinic

Transplantation | September 6, 2019 | Volume: 104 | Issue: 6 | Pages: 1229-1238

10.1097/tp.0000000000002947 | PMID 31490859 Get It

Background. We examined the 10-year experience of Mayo Clinic's kidney paired donation (KPD).We aimed to determine the benefits for the recipients of enrolled ABO/HLA compatible pairs and determine the factors associated with prolonged KPD waiting time. Methods. We performed a retrospective study of 332 kidney transplants facilitated by the Mayo 3-site KPD program from September 2007 to June 2018. Results. The median (interquartile range) time from KPD entry to transplantation was 89 days (42-187 days). The factors independently associated with receiving a transplant >3 months after KPD entry included recipient blood type O and calculated panel reactive antibodies ≥98%. Fifty-four ABO/HLA compatible pairs participated in KPD for the following reasons: cytomegalovirus mismatch (18.5% [10/54]), Epstein-Barr virus (EBV) mismatch (EBV) (9.3% [5/54]), age/size mismatch (51.9% [28/54]), or altruistic reasons (20.3% [11/54]). Cytomegalovirus and EBV mismatch were avoided in 90% (9/10) and 100% (5/5) of cases. Recipients who entered KPD for age/size mismatch and altruistic reasons received kidneys from donors with lower Living Kidney Donor Profile Index scores than their actual donor (median [interquartile range] 31.5 [12.3-47]; P < 0.001 and 26 (-1 to 46); P = 0.01 points lower, respectively). Median time to transplant from KPD entry for compatible pair recipients was 70 days (41-163 days), and 44.4% (24/54) of these transplants were preemptive. All chains/swaps incorporating compatible pairs included ABO/HLA incompatible pairs. Conclusions. KPD should be considered for all living donor/recipient pairs because the recipients of these pairs can derive personal benefit from KPD while increasing the donor pool for difficult to match pairs.
A Quantitative Analysis of Online Plastic Surgeon Reviews for Abdominoplasty
Oliver, Jeremie D. , Hu, M. , Lee, Gordon K. , Oliver, Jeremie D

Mayo Clinic

Plastic & Reconstructive Surgery | September 6, 2019 | Volume: 144 | Issue: 6 | Pages: 1110e-1111e

10.1097/prs.0000000000006213 | PMID 31764685 Get It

Chronic subthreshold cortical stimulation and stimulation-related EEG biomarkers for focal epilepsy
Khadjevand, Fatemeh, Stead, Matt, Lundstrom, Brian Nils, Lundstrom, Brian N. , Gompel, Jamie J. Van , Worrell, Gregory A.

Mayo Clinic

Brain Communications | September 6, 2019 | Volume: 1 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcz010 | PMID 31667473 Get It

Abstract Brain stimulation offers an alternative to focal resection for the treatment of focal drug-resistant epilepsy. Chronic subthreshold cortical stimulation is an individualized biomarker-informed open-loop continuous electrical stimulation approach targeting the seizure onset zone and surrounding areas. Before permanent implantation, trial stimulation is performed during invasive monitoring to assess stimulation efficacy as well as to optimize stimulation location and parameters by modifying interictal EEG biomarkers. We present clinical and neurophysiological results from a retrospective analysis of 21 patients, showing a median percent reduction in seizure frequency of 100% and responder rate of 89% with a median follow-up of 27 months. About 40% of patients were free of disabling seizures for a 12-month period or longer. We find that stimulation-induced decreases in delta (1–4 Hz) power and increases in alpha and beta (8–20 Hz) power during trial stimulation correlate with improved long-term clinical outcomes. These results suggest chronic subthreshold cortical stimulation may be an effective alternative approach to treating focal drug-resistant epilepsy and that short-term stimulation-related changes in spectral power may be a useful interictal biomarker and relate to long-term clinical outcome.